Wells Fargo analyst Derek Archila raised the firm’s price target on Ascendis Pharma (ASND) to $177 from $169 and keeps an Overweight rating on the shares. The analyst believes TransCon PTH gains approval in the first half of 2023 and its early access program and Takeda Pharmaceutical’s (TAK) Natpara exit in 2024 offer a lot of low-hanging fruit in the early launch. Archila expects the sales ramp to exceed expectations.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASND:
- Ascendis Pharma to initiate TransCon PTH U.S. expanded access program
- Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism
- Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference
- Ascendis Pharma’s Growth Hormone Shows Promising Results in China
- Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adult Patients with Hypoparathyroidism
